New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
ApexOnco Front Page
Recent articles
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.
Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?
Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.
But the Galaxies Lung-201 trial features notable omissions, plus toxicity.
Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.